Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
$ 271.31MInvested Capital
VS
Market
Sector
Industry
History
$ 14.31Close
$ 8.21 - $ 14.6 52-Week Range
Ticker Information
Ticker
TBPHCompany Name
THERAVANCE BIOPHARMA INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQTHERAVANCE BIOPHARMA INC - Invested Capital Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
TBPH - Inv. Capital Historical data
| Date | Total Debt | Shareholders Equity | Invested Capital |
|---|---|---|---|
| 6/30/2025 | $ 46.46M | $ 224.85M | $ 271.31M |
| 3/31/2025 | $ 48.16M | $ 165.98M | $ 214.14M |
| 12/31/2024 | $ 49.82M | $ 175.54M | $ 225.37M |
| 9/30/2024 | $ 44.98M | $ 185.65M | $ 230.63M |
| 6/30/2024 | $ 46.66M | $ 193.69M | $ 240.35M |
| 3/31/2024 | $ 47.9M | $ 204.87M | $ 252.77M |
| 12/31/2023 | $ 49.16M | $ 213M | $ 262.15M |
| 9/30/2023 | $ 50.83M | $ 246.13M | $ 296.96M |
| 6/30/2023 | $ 51.68M | $ 280.16M | $ 331.84M |
| 3/31/2023 | $ 51.19M | $ 370.56M | $ 421.75M |
Key Performance Insights, Last 5 Years
- THERAVANCE BIOPHARMA INC's latest trailing twelve months (TTM) Inv. Capital stands at $ 407.15M.
- Over the past 5 years, THERAVANCE BIOPHARMA INC's average Inv. Capital has been $ 327.44M.
- The median Inv. Capital for THERAVANCE BIOPHARMA INC during this period was $ 324.82M
- THERAVANCE BIOPHARMA INC reached its highest Inv. Capital over the past 5 years at $ 532.65M.
- The lowest Inv. Capital recorded by THERAVANCE BIOPHARMA INC in the same timeframe $ 214.14M
THERAVANCE BIOPHARMA INC's Inv. Capital vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
Inv. Capital Benchmarks
Similar metrics to Inv. Capital:
- Return on Invested Capital - [Calculation] Return on Invested Capital (ROIC) measures how well a company allocates its invested capital to profitable projects and/or investments. It is calculated as net income [NetIncCmn] divided by invested capital [InvCapital].
- Shareholders Equity - [Balance Sheet] A principal component of the balance sheet; in addition to [Liabilities] and [Assets]; that represents the total of all stockholders' equity (deficit) after all liabilities have been deducted.
- Cash Return on Invested Capital - [Calculation] Cash Return on Invested Capital (CROIC) measures how well a company uses its invested capital to produce cash. It is calculated as Free Cash Flow [FCF] divided by invested capital [InvCapital].
- Total Debt - [Balance Sheet] The total debt is a component of [Liabilities] that represents principle balances held in exchange for interest paid (also know as loans). Includes secured and unsecured bonds issued, commercial paper, notes payable credit facilities, lines of credit, capital lease obligations, operating lease obligations, and convertible notes.
- Enterprise Value - [Calculation] Enterprise value (EV) refers to the total value of a business and is frequently used as a more elaborate substitute for market capitalization. EV is calculated as a company's [MarketCap] plus its [Debt] minus cash and cash equivalents [CashnEq].
Definition of Invested Capital
[Calculation] Invested Capital is the total amount of money raised by a business in the form [Equity] and/or [Debt].Debt + Equity
(=) Inv. Capital Inv. Capital for THERAVANCE BIOPHARMA INC is calculated as follows: Debt [ $ 668.68M ] + Equity [ $ -261.54M ]
(=) Inv. Capital [ $ 407.15M ] TBPH - Invested Capital, Last 5 years
$ 214.14M
Minimum
Mar 31, 2025
$ 532.65M
Maximum
Sep 30, 2022
$ 327.44M
Average
$ 324.82M
Median
Inv. Capital Benchmark AnalysisMarket
The chart above depicts the distribution of Inv. Capital for companies in the Total Stock Market. The average Inv. Capital of the companies is $ 759.87M with a standard deviation of $ 1B.
The following table provides additional summary stats:
Inv. Capital in the Market:
| filtered constituents | 3.44K |
|---|---|
| min | $ -1.51B |
| max | $ 4.11B |
| average | $ 759.87M |
| median | $ 302.55M |
| std | $ 1B |